IN2013MU02828A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MU02828A IN2013MU02828A IN2828MU2013A IN2013MU02828A IN 2013MU02828 A IN2013MU02828 A IN 2013MU02828A IN 2828MU2013 A IN2828MU2013 A IN 2828MU2013A IN 2013MU02828 A IN2013MU02828 A IN 2013MU02828A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- saroglitazar
- present
- free acid
- amorphous form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2014/000551 WO2015029066A1 (en) | 2013-08-29 | 2014-08-28 | Polymorphic form of pyrrole derivative and intermediate thereof |
EP14802513.3A EP3039011A1 (en) | 2013-08-29 | 2014-08-28 | Polymorphic form of pyrrole derivative and intermediate thereof |
MX2016002612A MX371021B (es) | 2013-08-29 | 2014-08-28 | Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables. |
IN2828MU2013 IN2013MU02828A (tr) | 2013-08-29 | 2014-08-28 | |
US14/915,457 US9951009B2 (en) | 2013-08-29 | 2014-08-28 | Polymorphic form of pyrrole derivative and intermediate thereof |
PH12016500394A PH12016500394A1 (en) | 2013-08-29 | 2016-02-29 | Polymorphic form of pyrrole derivative and intermediate thereof |
ZA2016/01461A ZA201601461B (en) | 2013-08-29 | 2016-03-03 | Polymorphic form of pyrrole derivative and intermediate thereof |
US15/947,049 US20180297946A1 (en) | 2013-08-29 | 2018-04-06 | Polymorphic form of pyrrole derivative and intermediate thereof |
US15/947,044 US20180297945A1 (en) | 2013-08-29 | 2018-04-06 | Polymorphic form of pyrrole derivative and intermediate thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2828MU2013 IN2013MU02828A (tr) | 2013-08-29 | 2014-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013MU02828A true IN2013MU02828A (tr) | 2015-07-03 |
Family
ID=51947417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2828MU2013 IN2013MU02828A (tr) | 2013-08-29 | 2014-08-28 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9951009B2 (tr) |
EP (1) | EP3039011A1 (tr) |
IN (1) | IN2013MU02828A (tr) |
MX (1) | MX371021B (tr) |
PH (1) | PH12016500394A1 (tr) |
WO (1) | WO2015029066A1 (tr) |
ZA (1) | ZA201601461B (tr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107056671A (zh) | 2011-01-31 | 2017-08-18 | 卡迪拉保健有限公司 | 脂肪代谢障碍的治疗 |
EA201592020A1 (ru) | 2013-04-22 | 2016-05-31 | Кадила Хелзкэр Лимитед | Новая композиция для неалкогольной жировой болезни печени (нажбп) |
ES2889916T3 (es) | 2013-05-30 | 2022-01-14 | Cadila Healthcare Ltd | Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas |
TW201513857A (zh) | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
IN2013MU02470A (tr) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
WO2015033357A2 (en) | 2013-09-06 | 2015-03-12 | Cadila Healthcare Limited | An improved process for the preparation of pyrrole derivatives |
WO2016181409A1 (en) * | 2015-05-11 | 2016-11-17 | Cadila Healthcare Limited | Saroglitazar magnesium for the treatment of chylomicronemia syndrome - |
WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
WO2018104916A1 (en) | 2016-12-09 | 2018-06-14 | Cadila Healthcare Limited | Treatment for primary biliary cholangitis |
CN111727074A (zh) * | 2018-01-30 | 2020-09-29 | 凯诺斯医药有限责任公司 | 有机化合物的盐形式 |
WO2020183379A1 (en) * | 2019-03-11 | 2020-09-17 | Cadila Healthcare Limited | Novel salts, crystalline forms and premix of hypolipidemic agent |
US20220023262A1 (en) * | 2020-07-24 | 2022-01-27 | Cadila Healthcare Limited | Composition comprising high purity pyrrole derivative and method for preparation thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6713494B1 (en) * | 1996-08-28 | 2004-03-30 | Eli Lilly And Company | Amorphous benzothiophenes, methods of preparation and methods of use |
PT1051978E (pt) * | 1998-01-07 | 2012-11-20 | Meiji Seika Pharma Co Ltd | Composições de cefalosporina amorfa cristalograficamente estável e processo para a sua produção |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
US6514995B1 (en) | 2000-09-25 | 2003-02-04 | Advanced Research And Technology Institute, Inc. | Enediyne compounds and methods related thereto |
US6627760B1 (en) * | 2001-06-25 | 2003-09-30 | Astrazeneca Ab | Amorphous compound |
US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
WO2004000823A1 (en) * | 2002-06-21 | 2003-12-31 | Dr. Reddy's Laboratories Limited | Amorphous form of(-)-}2-}4-}(4-chlorophenyl)-phenyl methyl}-1-piperazinyl] ethoxy] acetic acid dihydrochloride (levocetririzine dihydrochloride) |
HRP20020614A2 (en) * | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
EP1587792B1 (en) * | 2003-01-27 | 2014-08-27 | Hanmi Science Co., Ltd. | Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof |
US20040266787A1 (en) * | 2003-03-25 | 2004-12-30 | Dr. Reddy's Laboratories Limited | Novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1-piperazinyl]ethoxy]acetic acid and process for the preparation thereof |
JP2007504226A (ja) * | 2003-09-03 | 2007-03-01 | ワイス | 非晶質状のラパマイシンの3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸との42−エステル、およびそれを含むその医薬組成物 |
AR052918A1 (es) * | 2005-02-25 | 2007-04-11 | Recordati Ireland Ltd | Clorhidrato de lercanidipina amorfo |
WO2007016435A2 (en) * | 2005-07-28 | 2007-02-08 | Isp Investments Inc. | Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
CN107056671A (zh) * | 2011-01-31 | 2017-08-18 | 卡迪拉保健有限公司 | 脂肪代谢障碍的治疗 |
ES2889916T3 (es) | 2013-05-30 | 2022-01-14 | Cadila Healthcare Ltd | Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas |
-
2014
- 2014-08-28 IN IN2828MU2013 patent/IN2013MU02828A/en unknown
- 2014-08-28 WO PCT/IN2014/000551 patent/WO2015029066A1/en active Application Filing
- 2014-08-28 US US14/915,457 patent/US9951009B2/en active Active
- 2014-08-28 MX MX2016002612A patent/MX371021B/es active IP Right Grant
- 2014-08-28 EP EP14802513.3A patent/EP3039011A1/en not_active Withdrawn
-
2016
- 2016-02-29 PH PH12016500394A patent/PH12016500394A1/en unknown
- 2016-03-03 ZA ZA2016/01461A patent/ZA201601461B/en unknown
-
2018
- 2018-04-06 US US15/947,044 patent/US20180297945A1/en not_active Abandoned
- 2018-04-06 US US15/947,049 patent/US20180297946A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ZA201601461B (en) | 2017-05-31 |
MX2016002612A (es) | 2016-10-04 |
MX371021B (es) | 2020-01-13 |
US20180297946A1 (en) | 2018-10-18 |
PH12016500394A1 (en) | 2016-05-16 |
WO2015029066A1 (en) | 2015-03-05 |
US20180297945A1 (en) | 2018-10-18 |
US20160207884A1 (en) | 2016-07-21 |
EP3039011A1 (en) | 2016-07-06 |
US9951009B2 (en) | 2018-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500394A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
PH12015501452A1 (en) | Novel quinolone derivatives | |
IN2014MN02106A (tr) | ||
MX2015005286A (es) | Procedimiento para la preparación de derivados del ácido biliar. | |
PH12014502605A1 (en) | Uracyl spirooxetane nucleosides | |
MX2015017861A (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
PH12014502040A1 (en) | Heterocyclyl compounds | |
IN2014MN02598A (tr) | ||
IN2014CN04530A (tr) | ||
PH12016500885A1 (en) | Novel heterocyclic compounds | |
WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
MY162397A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
IN2014MN02380A (tr) | ||
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
IN2013MU04056A (tr) | ||
IN2014MN02433A (tr) | ||
IN2014DN08296A (tr) | ||
PH12016500980A1 (en) | Amide derivatives for gpr119 agonist | |
WO2015102017A8 (en) | Processes for the preparation of lorcaserin | |
WO2014106826A3 (en) | Anthracycline analogue and uses thereof | |
IN2013MU03838A (tr) |